HUP0600031A3 - Kahalalide formulations and their use - Google Patents

Kahalalide formulations and their use

Info

Publication number
HUP0600031A3
HUP0600031A3 HU0600031A HUP0600031A HUP0600031A3 HU P0600031 A3 HUP0600031 A3 HU P0600031A3 HU 0600031 A HU0600031 A HU 0600031A HU P0600031 A HUP0600031 A HU P0600031A HU P0600031 A3 HUP0600031 A3 HU P0600031A3
Authority
HU
Hungary
Prior art keywords
kahalalide
formulations
kahalalide formulations
Prior art date
Application number
HU0600031A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Pharma Mar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar filed Critical Pharma Mar
Publication of HUP0600031A2 publication Critical patent/HUP0600031A2/hu
Publication of HUP0600031A3 publication Critical patent/HUP0600031A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Carbon And Carbon Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HU0600031A 2000-10-31 2001-10-31 Kahalalide formulations and their use HUP0600031A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24447100P 2000-10-31 2000-10-31
US24622900P 2000-11-06 2000-11-06
US34844901P 2001-10-19 2001-10-19
PCT/GB2001/004821 WO2002036145A2 (en) 2000-10-31 2001-10-31 Kahalalide f formulation

Publications (2)

Publication Number Publication Date
HUP0600031A2 HUP0600031A2 (en) 2006-05-29
HUP0600031A3 true HUP0600031A3 (en) 2012-02-28

Family

ID=27399760

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0600031A HUP0600031A3 (en) 2000-10-31 2001-10-31 Kahalalide formulations and their use

Country Status (22)

Country Link
US (1) US7473681B2 (https=)
EP (1) EP1330258B1 (https=)
JP (2) JP2004512370A (https=)
KR (1) KR100834138B1 (https=)
CN (1) CN1568192A (https=)
AT (1) ATE314084T1 (https=)
AU (2) AU1074902A (https=)
BR (1) BR0114912A (https=)
CA (1) CA2425627A1 (https=)
CY (1) CY1105009T1 (https=)
CZ (1) CZ20031211A3 (https=)
DE (1) DE60116359T2 (https=)
DK (1) DK1330258T3 (https=)
ES (1) ES2256305T3 (https=)
HK (1) HK1054192B (https=)
HU (1) HUP0600031A3 (https=)
IL (2) IL155297A0 (https=)
MX (1) MXPA03003704A (https=)
NO (1) NO331082B1 (https=)
NZ (1) NZ525243A (https=)
SK (1) SK286421B6 (https=)
WO (1) WO2002036145A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
US20050054555A1 (en) * 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
WO2003033012A1 (en) * 2001-10-19 2003-04-24 Pharma Mar, S.A. Kahalalide compounds for use in cancer therapy
GB0304367D0 (en) * 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
DK1572726T3 (da) * 2002-10-18 2011-03-28 Pharma Mar Sau 4-methylhexansyre-kahalalid F-forbindelse
NZ539093A (en) * 2002-10-18 2007-10-26 Pharma Mar Sau 4-methylhexanoic kahalaide F compound
US7507708B2 (en) 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
DE10329847A1 (de) * 2003-07-02 2005-01-20 Toximed Gmbh Pharmazeutischer Wirkstoff gegen Prostatakarzinome
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
GB0408958D0 (en) * 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds
DK1827500T3 (da) * 2004-10-26 2009-08-31 Pharma Mar Sa Pegyleret liposomal doxorubicin i kombination med ecteinescidin 743
RS50510B (sr) 2004-10-29 2010-03-02 Pharma Mar S.A., Sociedad Unipersonal Formulacije koje sadrže ekteinascidin i disaharid
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
WO2009052379A2 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Improved antitumoral treatments
AU2009209541A1 (en) * 2008-01-30 2009-08-06 Pharma Mar, S.A. Improved antitumoral treatments
CN101965192A (zh) * 2008-03-07 2011-02-02 法马马有限公司 改善的抗肿瘤治疗
WO2009135939A2 (en) * 2008-05-09 2009-11-12 Pharma Mar, S.A. Depsipeptide for use in cancer therapy
HRP20231233T1 (hr) 2017-04-27 2024-01-19 Pharma Mar, S.A. Antitumorski spojevi

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
JP2799483B2 (ja) 1988-03-09 1998-09-17 大塚製薬株式会社 インターロイキン−１β組成物の安定化方法
GB8819607D0 (en) 1988-08-17 1988-09-21 Wellcome Found Novel combination
IE64738B1 (en) 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
JP2971680B2 (ja) 1991-10-02 1999-11-08 山之内製薬株式会社 組織プラスミノーゲン活性化因子含有組成物
JPH0597703A (ja) 1991-10-04 1993-04-20 Yamanouchi Pharmaceut Co Ltd 改変型組織プラスミノーゲン活性化因子含有組成物
US5550124A (en) 1991-12-10 1996-08-27 University Of Southern California Use of peripheral-type benzodiazpine sites for treatment of CNS trauma or disease
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
GB9302046D0 (en) * 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
US6274551B1 (en) * 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
JP3927248B2 (ja) * 1995-07-11 2007-06-06 第一製薬株式会社 Ｈｇｆ凍結乾燥製剤
GB9601120D0 (en) 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
JPH1014581A (ja) 1996-07-08 1998-01-20 Morinaga Milk Ind Co Ltd ウサギ型マクロファージ・コロニー刺激因子及びこれをコードするｄｎａ断片
DE69719265T2 (de) 1996-09-06 2003-12-04 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute, Kumamoto Medizinische Zusammensetzung die Gewebeplasminogenaktivator und Nikotinamid enthält
JP4025394B2 (ja) * 1996-09-06 2007-12-19 財団法人化学及血清療法研究所 組織プラスミノーゲン活性化因子医薬組成物
GB9803448D0 (en) * 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
GB9807639D0 (en) 1998-04-14 1998-06-10 Kennedy Rheumatology Inst Anti-inflammatory agents
CN1322136A (zh) 1998-09-23 2001-11-14 马库斯·基普 用于选择性神经元辐射防护的神经亲免素类物质
GB0002952D0 (en) 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
US20050054555A1 (en) 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy

Also Published As

Publication number Publication date
EP1330258B1 (en) 2005-12-28
AU2002210749B2 (en) 2006-12-21
CN1568192A (zh) 2005-01-19
DE60116359D1 (de) 2006-02-02
JP2004512370A (ja) 2004-04-22
CZ20031211A3 (cs) 2003-09-17
KR20030044005A (ko) 2003-06-02
IL155297A0 (en) 2003-11-23
JP2010047601A (ja) 2010-03-04
PL360848A1 (en) 2004-09-20
MXPA03003704A (es) 2004-05-04
ATE314084T1 (de) 2006-01-15
US7473681B2 (en) 2009-01-06
CY1105009T1 (el) 2010-03-03
DE60116359T2 (de) 2006-09-28
AU1074902A (en) 2002-05-15
HK1054192A1 (en) 2003-11-21
SK5022003A3 (en) 2003-12-02
BR0114912A (pt) 2003-10-14
WO2002036145A2 (en) 2002-05-10
NO331082B1 (no) 2011-10-03
HK1054192B (en) 2006-09-08
NZ525243A (en) 2005-01-28
KR100834138B1 (ko) 2008-06-02
WO2002036145A3 (en) 2002-10-17
CA2425627A1 (en) 2002-05-10
SK286421B6 (sk) 2008-09-05
DK1330258T3 (da) 2006-05-22
NO20031860D0 (no) 2003-04-25
US20040067895A1 (en) 2004-04-08
IL155297A (en) 2010-05-31
ES2256305T3 (es) 2006-07-16
HUP0600031A2 (en) 2006-05-29
EP1330258A2 (en) 2003-07-30
WO2002036145A8 (en) 2003-10-23
NO20031860L (no) 2003-06-30

Similar Documents

Publication Publication Date Title
EG23122A (en) Pyrrolcarboxamides and pyrrolcarbothioamides
AU6336101A (en) Novel surfactants and formulations
HUP0204118A3 (en) 4-aminopicolinates and their use as herbicides
AU8729901A (en) Benzoylpyrazols and their use as herbicides
AU9667901A (en) Mycoattractants and mycopesticides
HUP0401911A3 (en) Pesticidal formulations and their use
GB0101035D0 (en) Formulation and use thereof
HUP0600031A3 (en) Kahalalide formulations and their use
HUP0301076A3 (en) Linezolid-crystal form ii and preparation thereof
HUP0300657A3 (en) Herbicidal composition preparation and use thereof
AU5073101A (en) Lipid composition and use thereof
IL153671A0 (en) Amphipathic linear peptides and formulations containing same peptides
EG22491A (en) Rest-breaking composition and use thereof
GB0026134D0 (en) Peptides and their use
AU8975701A (en) Novel composition and use
GB0007530D0 (en) Trityl-type compounds and their use
GB0021497D0 (en) Compounds and their use
GB0004534D0 (en) Hair treatment compositions and their use
AU2001277519A1 (en) Bio-probes and use thereof
AU5104101A (en) Composition and use
GB0200843D0 (en) Benzodioxinopyrroles their preparation and use
GB0004535D0 (en) Hair treatment compositions and their use
GB9929581D0 (en) Comjpositions and their use
GB9911606D0 (en) Composition and use
SI1330258T1 (sl) Formulacija kalahida f

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees